Linear IgA bullous dermatosis induced by nemvaleukin alfa, an engineered interleukin 2 molecule, in a patient with treatment-refractory metastatic melanoma.

Linear IgA bullous dermatosis (LABD) is characterized by linear deposition of IgA at the dermoepidermal junction. It is associated with medications, malignancies, and vaccinations.1 Here, we present a case of a patient with LABD treated with nemvaleukin alfa, a novel, engineered interleukin 2 (IL-2) receptor therapy currently in phase 2 investigation for treatment of advanced melanoma.